Analysis of PI-RADS 4 cases: Management recommendations for negatively biopsied patients

• Published in: European journal of radiology 2019-04, Vol.113, p.1-6
• Main Authors: Ullrich, T., Arsov, C., Quentin, M., Laqua, N., Klingebiel, M., Martin, O., Hiester, A., Blondin, D., Rabenalt, R., Albers, P., Antoch, G., Schimmöller, L.
• Format: Article
• Language: English
• Subjects: Aged; Biopsy, Large-Core Needle - standards; Cancer detection; Cross-Sectional Studies; Humans; Image-Guided Biopsy - methods; Image-Guided Biopsy - standards; Magnetic Resonance Imaging - methods; Magnetic Resonance Imaging, Interventional - methods; Male; Middle Aged; Neoplasm Grading; PI-RADS; Prospective Studies; Prostate - pathology; Prostate biopsy; Prostate cancer; Prostate MRI; Prostatic Neoplasms - pathology; Prostatitis - pathology
• ISSN: 0720-048X; 1872-7727
• DOI: 10.1016/j.ejrad.2019.01.030

•Re-biopsy of obvious, peripheral, negatively biopsied PI-RADS-4-lesions is recommended.•Negatively biopsied transition zone confined PI-RADS-4-lesions with overlaying signs of severe stromal hyperplasia rarely contain csPCa.•Targeted MR/US fusion biopsy alone can miss some csPCa.•In uncertain cases PSAD should be considered for biopsy decision. To evaluate if subgroups of patients assigned to MRI category PI-RADS 4 regarding clinical and MRI imaging aspects have distinct risks of prostate cancer (PCa) to facilitate adequate clinical management of this population, especially after negative targeted biopsy. This prospective, IRB approved single center cross-sectional study includes 931 consecutive patients after mp-MRI at 3 T for PCa detection. 193 patients with PI-RADS assessment category 4 received subsequent combined targeted MRI/US fusion-guided and systematic 12-core TRUS-guided biopsy as reference standard and were finally analyzed. The primary endpoint was PCa detection of PI-RADS 4 with MRI subgroup analyses. Secondary endpoints were analyses of clinical data, location of PCa, and detection of targeted biopsy cores. PCa was detected in 119 of 193 patients (62%) including clinically significant PCa (csPCa; Gleason score ≥3 + 4 = 7) in 92 patients (48%). MRI subgroup analysis revealed 95% PCa (73% csPCa) in unambiguous PI-RADS 4 index lesions without additional, interfering signs of prostatitis in the peripheral zone or overlaying signs of severe stromal hyperplasia in the transition zone according to PI-RADS v2. Transition zone confined PI-RADS-4-lesions with overlaying signs of stromal hyperplasia showed PCa only in 11% (4% csPCa). Targeted biopsy cores missed the csPCa index lesion in 7% of the patients. PSA density (PSAD) was significantly higher in PCa patients. Small csPCa can reliably be detected with mp-MRI by experienced readers, but can be missed by targeted MR/US fusion biopsy alone. Targeted re-biopsy of unambiguous (peripheral) PI-RADS-4-lesions is recommended; whereas transition zone confined PI-RADS-4-lesions with overlaying signs of stromal hyperplasia might be followed-up by re-MRI primarily.